Grail Q3 net loss widens
GRAL•Grail’s third-quarter net loss widened 16% year over year to $103.57 million, while revenue rose 4%. Galleri test revenue increased 14%, and the company said the FDA decision on the test is expected by early Q1 2027.
1. Quarterly results
Grail reported a third-quarter net loss of $103.57 million, up 16% year over year. Revenue rose 4%, while adjusted gross profit fell 20%.
2. Galleri test
Galleri test revenue increased 14%, with test volume up about 24% year over year to more than 56,000. The company cited promotional pricing initiatives and ongoing market education as factors supporting adoption and revenue growth.
3. FDA timeline
Grail said it received a favorable FDA panel vote for Galleri and anticipates an FDA decision on approval by early Q1 2027.
